Actively Recruiting
Phase III Study of Neoadjuvant Chemotherapy with Toripalimab Versus Chemotherapy Alone for HRHER2- Breast Cancer
Led by First Affiliated Hospital of Zhejiang University · Updated on 2025-05-18
194
Participants Needed
13
Research Sites
156 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and safety of neoadjuvant chemotherapy combined with Toripalimab for women with HRHER2- breast cancer in this randomized, open-label, phase III study. The goal is to explore treatment strategies combining chemotherapy with immunotherapy to provide more options and a potential basis for precision treatment of this breast cancer subtype. The main focus is to assess the rate of complete pathological response and RCB0-1 ratio after neoadjuvant treatment. Participants are assigned to one of two groups one receives neoadjuvant chemotherapy combined with Toripalimab, and the other receives neoadjuvant chemotherapy alone. The chemotherapy includes intravenous infusions of Epirubicin or liposomal doxorubicin plus Cyclophosphamide for 12 weeks, followed by Paclitaxel every 3 weeks for 12 weeks. The group receiving Toripalimab will have additional intravenous infusions of 240 mg every 3 weeks during both neoadjuvant chemotherapy and postoperative adjuvant therapy for a total duration of one year. During the study, participants will undergo various assessments to monitor treatment effects and safety. These include evaluations of tumor response, organ function tests, cardiac ultrasound, and electrocardiograms. Researchers will measure outcomes such as pathological complete response and event-free survival over periods of 2 to 5 years. Participants will also be monitored for adverse events and followed up regularly for treatment adherence and health status throughout the study duration.
CONDITIONS
Brief Title
Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)
Research Team
Z
Zhijun Dai, Professor
Y
Youyi Chen
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here